Direct-to-consumer genetic testing kits vary in predictions of disease risk

July 17, 2013, Emory University

(Medical Xpress)—An in-depth analysis and comparison study conducted by investigators at Emory's Rollins School of Public Health demonstrated variations in predicted disease risks by companies that offer direct-to-consumer personal genome testing.

Led by Cecile Janssens, PhD, research professor of Epidemiology, the team investigated DNA test results from three "direct- to-consumer" genome testing companies (23andMe, deCODEme, and Navigenics) to assess and compare their predictive abilities. Results show that predicted risks differed among the companies and were contradictory for certain traits in certain individuals.

The complete findings are available in the online edition of Genetics in Medicine.

"Although two of the companies that we studied are no longer operating, and sequencing is becoming less expensive and testing such as this is increasingly popular," explains Janssens. "The methods used for predicting these types of results are of important concern."

Test results provided by the three companies indicated an individual's risks for a large number of diseases. The study was conducted by creating DNA data for a hypothetical population of 100,000 individuals which is a less expensive and equally valid method for demonstrating the variations in predicted risk among the companies.

Predicted risks were calculated using the prediction methods of the three companies, obtained from their websites. Predicted risks were assessed and compared for six diseases: , prostate cancer, , Crohn disease, age-related , and .

The variations in predicted risks were explained by three factors:

  • The companies considered a different number of genetic variants in the risk calculations. Generally a larger difference in the number of variants implied more variation in predicted risks.
  • All three companies used an estimate for the average population disease risk as a starting point for their predictions. Differences in average risks affect predicted risks of all consumers to the same extent. For example, when the average odds is two times higher, all predicted odds are also two times higher.
  • The companies applied different mathematical formulas. The formulas of two companies led to an overestimation of risks when predicted risks were higher and even predicted risks that were higher than 100 percent.

"Our study provides insight into the methodology and performance of risk estimation for personal genome tests," Janssens explains. "Future efforts to design predictive models will benefit from understanding the strengths and limitations of these current models and formulas."

Explore further: DTC genetic tests neither accurate in their predictions nor beneficial to individuals

More information: … full/gim201380a.html

Related Stories

DTC genetic tests neither accurate in their predictions nor beneficial to individuals

May 30, 2011
Amsterdam, The Netherlands: Direct-to-consumer (DTC) genetic tests give inaccurate predictions of disease risks and many European geneticists believe that some of them should be banned, the annual conference of the European ...

Genetic testing kits get closer look in Loyola study

July 15, 2013
(Medical Xpress)—Several companies sell genetic testing directly to consumers, but little research has been done on how consumers experience such tests. The tests have raised questions about the validity and accuracy of ...

Meta-analysis confirms common painkillers increase risk of heart problems and death but suggests size of these risks can

May 29, 2013
NSAIDs have been the cornerstone in managing pain in people with inflammatory disorders like rheumatoid arthritis, and are some of the most commonly used drugs worldwide. Earlier research has linked their use with an increased ...

Comparing family history and genetic tests for predicting complex disease risk

October 15, 2012
In a new theoretical study, 23andMe, the personal genetics company, developed a mathematical model which shows that family history and genetic tests offer different strengths. The study results suggest that both family history ...

Patients see benefits and risks to direct-to-consumer genetics tests

May 10, 2012
Patients see potential benefits from direct-to-consumer genetic testing, but are also concerned about how test results will be used, and generally are unwilling to pay more than $10 or $20 for them, according to focus groups ...

Recommended for you

Peers' genes may help friends stay in school, new study finds

January 18, 2018
While there's scientific evidence to suggest that your genes have something to do with how far you'll go in school, new research by a team from Stanford and elsewhere says the DNA of your classmates also plays a role.

Can mice really mirror humans when it comes to cancer?

January 18, 2018
A new Michigan State University study is helping to answer a pressing question among scientists of just how close mice are to people when it comes to researching cancer.

Two new breast cancer genes emerge from Lynch syndrome gene study

January 18, 2018
Researchers at Columbia University Irving Medical Center and NewYork-Presbyterian have identified two new breast cancer genes. Having one of the genes—MSH6 and PMS2—approximately doubles a woman's risk of developing breast ...

A centuries-old math equation used to solve a modern-day genetics challenge

January 18, 2018
Researchers developed a new mathematical tool to validate and improve methods used by medical professionals to interpret results from clinical genetic tests. The work was published this month in Genetics in Medicine.

Epigenetics study helps focus search for autism risk factors

January 16, 2018
Scientists have long tried to pin down the causes of autism spectrum disorder. Recent studies have expanded the search for genetic links from identifying genes toward epigenetics, the study of factors that control gene expression ...

Group recreates DNA of man who died in 1827 despite having no body to work with

January 16, 2018
An international team of researchers led by a group with deCODE Genetics, a biopharmaceutical company in Iceland, has partly recreated the DNA of a man who died in 1827, despite having no body to take tissue samples from. ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.